
Prem Soman, MD, PhD, MASNC, spoke with Cardiovascular Business about the open-label extension of the ATTRibute-CM trial.
” … [I]t’s important to go out there and find these patients, diagnose them and treat them. It’s been a remarkable transformation in a field that, less than 10 years ago, we thought it was a rare disease and we had no therapy. Now we know that it’s a prevalent disease. If you look for it, you’ll find it.”
– Prem Soman, MD, PhD, MASNC
ASNC Past President discussing the latest ATTRibute-CM results
In a new video interview with Cardiovascular Business, ASNC Past President Prem Soman, MD, PhD, MASNC, summarized the findings of the open-label extension(OLE) of the ATTRibute-CM trial. Dr. Soman explained the implications of the findings for patients and their physicians.
The OLE evaluated the long-term efficacy and safety of acoramidis through month 54. “In this OLE, we see that, at month 54, early therapy and continuous therapy [with acoramidis] … has a survival advantage both for all-cause mortality and cardiovascular mortality and for cardiovascular hospitalization,” Dr. Soman said. “… It’s important to go out there, find these patients, diagnose them, and treat them.” Dr. Soman also detailed when clinicians should “think of amyloid” during patient evaluations and recommend radionuclide imaging. The clinical trial results were presented at ACC.26 and simultaneously published in JAMA Cardiology.
Article Type
News & Announcements
Category
Education, Guidelines & Quality, Publications
Related Posts
JNC Editor Challenges Nuclear Cardiology Community to Advance Inflammation Imaging and Clinical Evidence
Advancing molecular imaging of myocardial inflammation will require a concerted effort from…
Cardiac Amyloidosis and Suspected Coronary Disease: What Would You Do Next?
An 80-year-old man with chest pain and known ATTR cardiac amyloidosis, diagnosed…
CMS Releases Final Medicare Physician Fee Schedule and Hospital Outpatient Payment Rates and Policies for 2027
The Centers for Medicare & Medicaid Services (CMS) has released the 2027…


